Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...

With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...

Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

The National Medical Products Administration in China has approved two Sanofi (SNY) medicines for rare hematologic diseases: Qfitlia for ...

Gemini Space Station, a cryptocurrency company founded by Cameron and Tyler Winklevoss, said that its affiliate Gemini Titan has received a designated contract market license. The company's COO will ...

Dow Jones Top Company Headlines at 9 AM ET: Altria CEO Gifford to Retire in 2026, CFO Mancuso Tapped to Take Over | Lilly ... Altria CEO Gifford to Retire in 2026, CFO Mancuso Tapped to Take Over ...

Sanofi ( ($SNY) ) just unveiled an update. In December 2025, Sanofi announced the completion of its acquisition of Vicebio Ltd, which enhances its ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Alnylam Pharmaceuticals, Inc. ("Alnylam") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with ...